Clinical Trial to Determine the Effect of a Mouthwash on the Preservation of the Ecology of the Oral Microbiome and Its Compatibility With Health

NCT ID: NCT04973358

Last Updated: 2021-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-30

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The microbiota of the human body is essential to life, and plays an essential role in the protection and development of various pathological conditions. There is a symbiotic or mutualistic relationship between humans and their microbiota. However, when the microbiota becomes dysbiotic, it is associated with pathological conditions. In the oral cavity, dysbiosis is responsible for caries and periodontal pathologies, but other associations have been demonstrated or are suspected with distant pathologies (rheumatoid arthritis, Alzheimer's disease). Mouthwashes are used therapeutically or daily to maintain oral health. The main studies reporting their effects on the ecology of the oral microbiota are for the most part limited to Pasteurian culture techniques (40% of bacteria are not yet cultivable). The advent of new generations of sequencing allows to overcome this limitation and to explore the complexity of bacterial communities, i.e. the symbiosis or dysbiosis of the entire bacterial ecosystem. The control of the oral microbiota to prevent pathologies requires a better knowledge of the oral microbial ecology and will allow the development of new approaches that consider the process of biofilm formation and the disruption of bacterial communication networks. The effects of daily mouthwash must therefore be studied at the level of the entire bacterial community.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Buccal Microbiota

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BuccoTherm

buccotherm mouthwash

Group Type EXPERIMENTAL

buccotherm mouthwash

Intervention Type OTHER

twice a day for 14 weeks

Placebo

placebo mouthwash

Group Type PLACEBO_COMPARATOR

placebo mouthwash

Intervention Type OTHER

twice a day for 14 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

buccotherm mouthwash

twice a day for 14 weeks

Intervention Type OTHER

placebo mouthwash

twice a day for 14 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older:
* with at least 20 permanent natural teeth, excluding crowns;
* affiliated to a social security system;
* having received information about the protocol and having given their free, informed and written consent.

Exclusion Criteria

* with periodontitis in the month prior to inclusion;
* with significant carious lesions deeply modifying the oral microbiota in the month prior to inclusion;
* having undergone oral surgical treatment within 3 months prior to inclusion;
* wearing orthodontic appliances;
* having undergone periodontal procedures in the month prior to inclusion;
* suffering from severe chronic pathologies deemed incompatible with study entry;
* allergic to one of the swab components;
* allergic to any of the components of the BUCCOTHERM mouthwash or the placebo;
* on drugs that may cause gingival hypertrophy, such as Hydantoins (phenytoin), Dihydropyridines, Diltiazem or Ciclosporin;
* Medications that can cause gingival bleeding (anticoagulants, antiplatelet agents and aspirin);
* Antibiotic therapy or professional scaling in the month prior to inclusion;
* having used oral or topical antibiotics, antiseptics and/or antifungals (e.g., mouthwash, dental gels, etc.) in the month prior to inclusion.
* Subjects with poor written and spoken French language skills;
* previously included in the BUCCOTHERM study;
* simultaneously participating in another trial that may interfere with the conduct of the BUCCOTHERM study or in a period of exclusion after participation in another clinical study;
* protected persons (adults under legal protection (legal guardianship, curatorship, tutorship), persons deprived of liberty, pregnant or breastfeeding women, women of childbearing age without effective contraception (estrogen-progestin treatments, IUD, tubal ligation), minors.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Meuric Vincent

Role: PRINCIPAL_INVESTIGATOR

CHU Rennes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Rennes

Rennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mevel Nicolas

Role: CONTACT

02 99 28 25 55

Ganivet Anne

Role: CONTACT

02 99 28 25 55

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

MEURIC Vincent

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-A01541-40

Identifier Type: OTHER

Identifier Source: secondary_id

35RC21_9796_BUCCOTHERM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prevention of Adult Caries Study (PACS)
NCT00357877 COMPLETED PHASE3
Effects of Probiotics on Oral Health
NCT02444182 COMPLETED PHASE1/PHASE2
NAC Prevents Toxicity of Teeth Bleaching
NCT03534115 COMPLETED EARLY_PHASE1